Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABATO trial of early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection
NL-OMON44940Phase 3Active, not recruiting
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Jan 2016
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Staphylococcus aureus bloodstream infection (SABSI) (2 arms), sponsored by Heinrich Heine University Düsseldorf. Primary endpoint: SAB-related complication within 90 days. Started Jan 2016; status: active, not recruiting.
02
Conditions
Staphylococcus aureus bloodstream infection (SABSI)
Beyond the preview
Go deeper on NL-OMON44940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44940.